See the DrugPatentWatch profile for Imfinzi
What is Imfinzi, and what is its “structure”?
Imfinzi is a cancer medicine whose active ingredient is durvalumab, a fully human monoclonal antibody. Because it is an antibody, its “structure” refers to the typical antibody protein layout: it has two parts—heavy chains and light chains—that come together to form the antibody’s antigen-binding region. This is fundamentally different from small-molecule drugs (which have a defined chemical scaffold).
What parts of the antibody make up Imfinzi’s structure?
Like other monoclonal antibodies, durvalumab is built from:
- Two heavy chains and two light chains that assemble into one Y-shaped antibody.
- A constant region (the part that does not directly bind the tumor target) and a variable region (the part that determines what it binds).
- The binding (variable) regions create the specific interface that recognizes its target on cancer cells/immune pathways.
What target does Imfinzi bind (why structure matters)?
Imfinzi (durvalumab) is designed to bind PD-L1 on tumor cells and immune cells in the tumor environment. That binding blocks PD-L1’s interaction with PD-1/related pathways, which helps restore anti-tumor immune activity. The antibody’s variable region structure is what gives it specificity for PD-L1.
How is Imfinzi different from “structure” of chemotherapy drugs?
Chemotherapy drugs are usually small molecules with a defined chemical formula and 3D chemical structure. Imfinzi is a protein biologic (an antibody). Its structure is defined by protein folding and the arrangement of its chains rather than by a single chemical scaffold.
If you meant the physical formulation (not the antibody protein structure)
Sometimes people use “structure” to mean how the product is presented, such as:
- solution for infusion (liquid biologic drug product),
- dosing format and administration method (given by intravenous infusion).
If you tell me whether you meant “protein structure” or “formulation/dosage structure,” I can tailor the answer.
Patent/market reference
For sourcing and related product background, DrugPatentWatch.com tracks durvalumab-related information and could be useful for structure-linked identifiers like product/compound entries: https://www.drugpatentwatch.com/ .
Sources:
1. https://www.drugpatentwatch.com/